US 11,903,907 B2
Soluble honokiol derivatives
Joen-Rong Sheu, Taipei (TW); Fa-Kung Lee, Taipei (TW); Chih-Cheng Chien, Taipei (TW); Chih-Ming Ho, Taipei (TW); Chao-Chien Chang, Taipei (TW); Cheng-Ying Hsieh, New Taipei (TW); and Jing-Ping Liou, Taipei (TW)
Assigned to TAIPEI MEDICAL UNIVERSITY, Taipei (TW); and CATHAY GENERAL HOSPITAL, Taipei (TW)
Filed by TAIPEI MEDICAL UNIVERSITY, Taipei (TW); and CATHAY GENERAL HOSPITAL, Taipei (TW)
Filed on Jul. 17, 2020, as Appl. No. 16/931,959.
Application 16/931,959 is a division of application No. 16/169,322, filed on Oct. 24, 2018, abandoned.
Claims priority of provisional application 62/576,464, filed on Oct. 24, 2017.
Prior Publication US 2020/0358554 A1, Nov. 12, 2020
Int. Cl. A61K 31/05 (2006.01); H04L 27/20 (2006.01); A61P 25/00 (2006.01); A61K 9/00 (2006.01); H03M 13/11 (2006.01); H03M 13/25 (2006.01); H03M 13/27 (2006.01); H03M 13/37 (2006.01); H03M 13/00 (2006.01); H04L 1/00 (2006.01); H03M 13/15 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 9/0019 (2013.01); A61P 25/00 (2018.01); H03M 13/1165 (2013.01); H03M 13/255 (2013.01); H03M 13/2707 (2013.01); H03M 13/2778 (2013.01); H03M 13/3761 (2013.01); H03M 13/3769 (2013.01); H03M 13/6356 (2013.01); H03M 13/6362 (2013.01); H04L 1/0041 (2013.01); H04L 1/0045 (2013.01); H04L 1/0057 (2013.01); H04L 1/0065 (2013.01); H04L 1/0067 (2013.01); H04L 1/0071 (2013.01); H03M 13/152 (2013.01); H04L 27/20 (2013.01)] 18 Claims
 
1. A method of antagonizing glycoprotein VI receptor, comprising administration of a therapeutically effective amount of the following compound of Formula (I) to a subject:

OG Complex Work Unit Chemistry
wherein
X is (CH2)1-6;
R1 is phosphate or carbonate;
R2 and R3 are each independently C2-6alkenyl, C1-10alkyl, —O—C1-10alkyl or —NH—C1-10alkyl, wherein the alkyl or alkenyl is unsubstituted or substituted; and
R4 and R5 are each independently one to three H, halogen, —OH, —NH2, NO2, C1-10alkyl, C2-6alkenyl, —O—C1-10alkyl or —NH—C1-10alkyl;
or a pharmaceutically acceptable salt thereof;
wherein the compound or a pharmaceutically acceptable salt thereof is administered by intravenous injection; and
wherein the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.01 to about 1.0 mg per kg body weight.